Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Suven Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -583.31%.
The historical rank and industry rank for Suven Life Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:
BOM:530239'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -451.55 Med: -105.39 Max: 42.93
Current: -192.11
During the past 13 years, Suven Life Sciences's highest ROC (Joel Greenblatt) % was 42.93%. The lowest was -451.55%. And the median was -105.39%.
BOM:530239's ROC (Joel Greenblatt) % is ranked worse than 91.04% of 982
companies
in the Drug Manufacturers industry
Industry Median: 10.525
vs BOM:530239: -192.11
Suven Life Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 21.20% per year.
Suven Life Sciences (BOM:530239) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Suven Life Sciences ROC (Joel Greenblatt) % Related Terms
Suven Life Sciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Suven Life Sciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530239 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suven Life Sciences ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Suven Life Sciences's ROC (Joel Greenblatt) % falls into.
Suven Life Sciences ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -583.31% mean?
Suven Life Sciences (BOM:530239) has a ROC (Joel Greenblatt) % of -583.31% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Suven Life Sciences and its competitors. According to the industry distribution chart, Suven Life Sciences ranks #894 out of 982 companies in the Drug Manufacturers industry, placing it in the top 91%.
Is Suven Life Sciences' ROC (Joel Greenblatt) % too high?
Suven Life Sciences' current ROC (Joel Greenblatt) % is -583.31%. Based on the distribution chart, Suven Life Sciences ranks #894 out of 982 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Suven Life Sciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suven Life Sciences ranks #894 out of 982 companies for ROC (Joel Greenblatt) %. This places Suven Life Sciences in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 10.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.53, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Suven Life Sciences and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suven Life Sciences's current ROC (Joel Greenblatt) % is -583.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (BOM:530239) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹123.98, compared to a current price of ₹336.55 — trading 171.5% above its estimated fair value. The current ROC (Joel Greenblatt) % is -583.31%. Suven Life Sciences' overall GF Score™ is 40/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Suven Life Sciences (BOM:530239), the current ROC (Joel Greenblatt) % is -583.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suven Life Sciences (BOM:530239) Overvalued in 2026?
Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued.
The current stock price of ₹336.55 is trading 171.5% above its estimated GF Value™ of ₹123.98.
GuruFocus considers Suven Life Sciences to be Significantly Overvalued.
Key valuation signals for BOM:530239:
ROC (Joel Greenblatt) %: -583.31%
GF Value™: ₹123.98 vs. price of ₹336.55 (171.5% above fair value)
No single metric tells the full story. See the BOM:530239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
40GF Score
Get the complete analysis for BOM:530239
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530239 has been successfully added to your 
